CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its aim is to ensure appropriate supply of Ipratropium Bromide inhaler. 2. The Guidance 2.1 Clinical condition Indication of situation/condition Relevant National Guidance for inclusion for patient exclusion Cautions/ Need for further advice Action if patient excluded Action if patient declines Additional Action to be taken Child in respiratory distress and oxygen saturations 92% and above in room AIR as a combination with Salbutamol inhaler Current BNF Drug information leaflet Any child over 1 year of age with the above signs and symptoms Child < 1 year referred with a suspected diagnosis of bronchiolitis as they are unlikely to benefit Children with signs of upper airway obstruction (Stridor/barking cough) Risk of glaucoma, bladder outflow obstruction. Cystic fibrosis interactions Document in patient notes and inform clinician Document in patient notes and inform clinician ne 2.2 Characteristics of Health Care Professionals Class of Healthcare professional for whom PGD is applicable and qualifications Specialist competencies or qualifications considered relevant to the medicines used in the direction. Page 1 of 10 Registered nurses (RN Child or RSCN) with at least 12 months post registration experience who have a regular contract in that area. (e.g. no agency or bank workers) Comply with NMC s of Medicine Management. PGD workbook and Child Health Drug workbook must be completed
Competencies required: Continuing training and education Practical assessment must be completed (see competency framework) The responsibility for continuing education lies with the individual practitioner. Yearly updates will be provided through the Paediatric Pain Study morning 2.3 Description of treatment Name and Form of Medicine E.g. tablets Legal status Prescription Only Medicine (POM) / General Sales List (GSL), Pharmacy Only (PO) Licensed / Unlicensed / Offlicensed (State rationale for un/off-licensed use) Dose/s (where range is applicable include criteria for deciding on a dose) Route/Method of Administration Frequency of Administration Total dose/number of times treatment can be administered over what time Side Effects of drugs (to include potential adverse reactions) and any monitoring required Procedure for reporting Adverse Drug Reactions (ADR) Special consideration for patients receiving concurrent medication Information on follow-up treatment if needed Written / verbal advice for patient / carer before / after treatment. Product information leaflet should be given to the patient / carer Method of recording supply / administration, names of HCP, patient identifiers, sufficient to enable audit trail. Atrovent Inhaler CFC-Free 20 Mcg/actuation pressurised inhalation solution Ipratropium bromide POM Licensed 1yr 6yrs = 1 puff (20mcg) 6yrs 18yrs = 2puffs (40mcg) Inhaled using appropriate sized spacer Can initially be repeated at 20-30 minute intervals if prescribed on a drug chart. 1 dose under PGD Dry mouth, nausea, gastro-intestinal motility disorder, throat irritation, cough, headache, dizziness, visual disturbance blurring (BNF 15/16) Trust Procedure. The event is recorded on DATIX and the yellow card completed before sending to pharmacy. none none none The PGD should be recorded on EPMA If not an inpatient then it should be recorded in the patient s notes Page 2 of 10
3. Monitoring compliance and effectiveness Element to be monitored Lead Tool Frequency Reporting arrangements Acting on recommendations and Lead(s) Change in practice and lessons to be shared Compliance of following the PGD process will be yearly Monitoring of drug doses will be monitored monthly. Sarah Fox and Kim Philp Retrospective audit of patient notes for auditing the PGD process (see appendix 3) EPMA report will be used to monitor doses. A full audit using the attached tool will be completed yearly and a report will be written. EPMA reports are produced monthly The report will be shared at the Paediatric audit and guidelines meeting and the PGD working Group. Monthly monitoring of doses using the EPMA report will be shared with the Matron for Child Health. Paediatric audit and Guidelines PGD working group Required actions will be identified and completed in a specified timeframe Required changes to practice will be identified and actioned within 3-6 months. A lead member of the team will be identified to take each change forward where appropriate. Lessons will be shared with all the relevant stakeholders 4. Equality and Diversity 4.1. This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement which can be found in the 'Equality, Diversity & Human Rights Policy' or the Equality and Diversity website. 4.2. Equality Impact Assessment The Initial Equality Impact Assessment Screening Form is at Appendix 2. Page 3 of 10
Appendix 1. Governance Information Document Title Date Issued/Approved: 1 Jan 16 Ipratropium Bromide inhaler Patient Group Direction Child Health Date Valid From: 1 Jan 16 Date Valid To: 1 Jan 19 Directorate / Department responsible (author/owner): Kim Philp, Staff Nurse Contact details: 01872 252089 Brief summary of contents Suggested Keywords: Target Audience Executive Director responsible for Policy: Date revised: This document replaces (exact title of previous version): Approval route (names of committees)/consultation: Divisional Manager confirming approval processes Name and Post Title of additional signatories Describes the process for supplying Ipratropium Bromide inhaler in the Child Health Department using a PGD PGD, Ipratropium Bromide inhaler solution, Paediatric, Children RCHT PCH CFT KCCG Medical Director N/A New Medicines Practice Committee PGD working group (child health) Dr Chris Williams Dr Chris Williams, Paediatric Consultant Mary Baulch/Mel Gilbert, Matron for Child Health Phil Dale, Paediatric Pharmacist Name and Signature of Divisional/Directorate Governance Lead confirming approval by specialty and divisional management meetings {Original Copy Signed} Name: Helen Ross Mc-Gill Signature of Executive Director giving approval Page 4 of 10 {Original Copy Signed} Publication Location (refer to Policy Internet & Intranet Intranet Only
on Policies Approvals and Ratification): Document Library Folder/Sub Folder Links to key external standards Related Documents: Training Need Identified? Clinical/Paediatrics NICE(2013) Good practice guidelines- Patient Group Directions none Comply with NMC s of Medicine Management. PGD workbook and Child Health Drug Workbook must be completed. (See competency framework- Procedural Guidelines for Developing, Implementing and Reviewing the Supply or Administration of Medicines under a Patient Group Direction (PGD)). Version Control Table Date Version Summary of Changes Changes Made by (Name and Job Title) 1 Jan 16 V1.0 Initial Issue Kim Philp Staff Nurse [Please complete all boxes and delete help notes in blue italics including this note] All or part of this document can be released under the Freedom of Information Act 2000 This document is to be retained for 10 years from the date of expiry. This document is only valid on the day of printing Controlled Document This document has been created following the Royal Cornwall Hospitals NHS Trust Policy on Document Production. It should not be altered in any way without the express permission of the author or their Line Manager. Page 5 of 10
Appendix 2. Initial Equality Impact Assessment Form Name of Name of the strategy / policy /proposal / service function to be assessed (hereafter referred to as policy) (Provide brief description): Ipratropium Bromide inhaler Patient Group Direction Child Health Directorate and service area: Is this a new or existing Policy? Clinical/Paediatrics New Name of individual completing Telephone: assessment: Kim Philp 1. Policy Aim* Who is the strategy / policy / proposal / service function aimed at? 7. The Impact Please complete the following table. Are there concerns that the policy could have differential impact on: Equality Strands: Rationale for Assessment / Existing Evidence Age Sex (male, female, transgender / gender reassignment) Race / Ethnic communities /groups 01872 252089 As per paragraph 1 of this document. 2. Policy Objectives* As per paragraph 1 of this document. 3. Policy intended Outcomes* 4. *How will you measure the outcome? 5. Who is intended to benefit from the policy? 6a) Is consultation required with the workforce, equality groups, local interest groups etc. around this policy? b) If yes, have these *groups been consulted? C). Please list any groups who have been consulted about this procedure. As per paragraph 1 of this document. As per paragraph 3 of this document All paediatric patients Page 6 of 10
Disability - Learning disability, physical disability, sensory impairment and mental health problems Religion / other beliefs Marriage and civil partnership Pregnancy and maternity Sexual Orientation, Bisexual, Gay, heterosexual, Lesbian You will need to continue to a full Equality Impact Assessment if the following have been highlighted: You have ticked in any column above and consultation or evidence of there being consultation- this excludes any policies which have been identified as not requiring consultation. or Major service redesign or development 8. Please indicate if a full equality analysis is recommended. 9. If you are not recommending a Full Impact assessment please explain why. Signature of policy developer / lead manager / director Date of completion and submission Names and signatures of members carrying out the Screening Assessment 1. Kim Philp 2. Keep one copy and send a copy to the Human Rights, Equality and Inclusion Lead, c/o Royal Cornwall Hospitals NHS Trust, Human Resources Department, Knowledge Spa, Truro, Cornwall, TR1 3HD A summary of the results will be published on the Trust s web site. Signed _Kim Philp Date 5/1/16 Page 7 of 10
Appendix 3. Audit tool PATIENT GROUP DIRECTIONS (PGD) AUDIT- 411 AREA OF AUDIT... NAME OF AUDITOR... DATE OF AUDIT.. 1. : The PGD documentation is accessible and up to date Practitioners surveyed confirmed that the PGD is accessible for reference at consultations (min number surveyed 10% of signatories) 100% 10 staff Copies of the PGD are located in the areas stated within the PGD 100% 1 area 2. : Local practice meets the standards detailed within the PGD Patients treated under the PGD for stated clinical indication only. (Min number of patient records surveyed should be at least 20 records or 50% (whichever is smaller)). Patients included for treatment under the PGD fit the inclusion criteria. The practitioners operating under the PGD are confirmed as competent to use PGDs (surveyed 10% of signatories) Page 8 of 10
3. : The following information is recorded in the patient record by the practitioners using the PGD (min number of patient records surveyed should be at least 20 records or 50% (whichever is smaller)). The name of the medicine The dose of the medicine The practitioners name The date when the patient received treatment under the PGD The practitioners signature Page 9 of 10
: The minimum records kept for audit purposes: (Gwithian and PAC only) The date of supply (record sheets) 100% 5 The patients name (record sheets) 100% 5 A unique identifier for the patient (NHS no) (record sheets) The practitioners name (record sheets) 100% 5 100% 5 4. : The reporting of adverse of clinical incidents (min number of patient records surveyed at least 20 records, or 50% (whichever is smaller)) Any adverse clinical incidents involving the medicine have been recorded via the local clinical incident reporting policy 0% N/A of incidents identified 5. : Education and training for using a PGD There is an individual identified who is responsible for ensuring the practitioners are trained and competent. (NB: training records should be available) Individual training records indicate that practitioners are ensuring they are updated. (min sample 10% of signatories) PGD update is included within paediatric pain study morning. 100% 100% N/A Page 10 of 10